Anew Labs (新生探途)

ByteDance's AI drug-discovery team, spun out in 2026 with a US$290M angel round and four preclinical programs.

1. Core Product / Service

Anew Labs is ByteDance's in-house AI drug-discovery group, which started hiring in late 2020 and was formally assembled in 2021. In June 2026 ByteDance moved the team, platform and pipeline into a new independent company [1][2]. It also uses the name Anew Therapeutics for its US and Singapore entities; a Singapore entity, Anew Therapeutics Pte Ltd, appears as the applicant on IL-17A small-molecule patent filings [7].

The computational stack is a family of in-house models [1][3]:

• AnewFold — structure prediction, building on ByteDance's open-source Protenix (an AlphaFold3-class model).
• AnewSampling — protein–ligand conformational dynamics.
• AnewOmni — all-atom molecule generation.
• AnewDesign — design tooling, including the open-source PXDesign protein-binder designer.
• AnewMind — an agent/reasoning layer.

Earlier descriptions also list AnewFEP (free-energy calculation) and AnewSynth (synthesizability prediction).

Pipeline. There are four preclinical programs spanning small molecules, antibodies and cyclic peptides [1][4]. The lead is an oral small molecule designed to block all three IL-17 dimers (IL-17A/A, A/F and F/F). It is in lead optimization and was first presented at the American Association of Immunologists meeting in April 2026 [1]. A second disclosed program targets IL-4R for atopic dermatitis [1]. Targets for the other programs are not disclosed.

Wet-lab model: not disclosed. No lab site, lab size or CRO partner has been named. One analysis describes the company as "compute-heavy, experiment-light" and suggests it may build its own lab, partner, or outsource to Chinese CROs, but that is the author's inference [1]. Sino Biopharm's strategic stake is widely read as a way to add experimental, clinical and regulatory capacity the team lacks [2]. Compute is supplied by ByteDance's Volcano Engine [1].

2. Target Users & Pain Points

Anew mainly develops its own drugs rather than selling a platform. The IL-17 program targets immunology indications such as psoriasis, where approved IL-17 drugs are injectable antibodies. An oral small molecule that hits all three dimers would be a more convenient alternative, if it works. The broader goal is to show that a structure-prediction and generative-design stack built by a large tech company can produce clinical-quality assets.

3. Competitive Landscape

4. Unique Observations

• Capital follows pedigree, not pipeline. Anew's US$1.5B post-money valuation came with all four programs still preclinical. Among the Chinese AI-native drug startups founded in 2023 or later, it, Aureka and Pinnacle took most of the money, and none of the three is a pure domestic academic spin-out.
• The spin-out reason is organizational. Reports quote the rationale that drug R&D's "ten years, one billion dollars" timeline cannot share an organization with internet-product cycles, because "two clocks in one organization" misalign incentives and reviews [2]. This repeats the Alphabet → Isomorphic logic.
• The valuation is mostly a platform bet. One financial outlet estimated the residual pipeline value at about US$0.5B against the US$1.5B headline [6]. No clinical data exists yet.
• "Founded 2026" understates the team's age. The legal entity is new, but the team and IL-17 work date back to 2021. Comparing it with other new Chinese startups by registration date overstates how fast it moved.

5. Financials / Funding

• Angel / first external round (Sept 2026): US$290M at roughly US$1.5B post-money [1][4][5]. Reported RMB-equivalent valuations differ (¥10B vs ¥12B).
  • Leads: HongShan (HSG), IDG and Hillhouse; 5Y Capital co-led.
  • Followers: Gaorong, Primavera and Boyu.
  • Strategic investors: Sino Biopharm (中国生物制药) and the Shanghai Future Industry Fund.
• Ownership: ByteDance retains about 56% [1][4].
• Revenue: none disclosed. No platform-licensing business has been announced.

6. People & Relationships

• Head: 刘凯 (Liu Kai), about seven years as a healthcare investor at IDG and Volcanics Venture before leading ByteDance's AI-drug team [1].
• Team: about 50 people, under 100 in total; the website listed 36 core members in May 2026 [1]. Some early core members, including leads on AI-for-science and Protenix, have since left to found their own companies.
• Scientific advisors: 刘勇军 (former president of Innovent), 马骥 (former Amgen chief scientist) and 邹华 (Takeda) [1].
• Parent / anchor shareholder: ByteDance.
• Investors: HongShan, IDG, Hillhouse, 5Y Capital, Gaorong, Primavera, Boyu, Sino Biopharm.
• Peers: isomorphic-labs, xaira-therapeutics, insilico-medicine, aureka-bio, pinnacle-medicines, aipher.

Sources

1. Huxiu — https://www.huxiu.com/article/4896593.html
2. Huxiu — https://www.huxiu.com/article/4892145.html
3. ifeng Tech — https://tech.ifeng.com/c/8wVpyaYIQWr
4. The Paper — https://m.thepaper.cn/newsDetail_forward_34081481
5. 36Kr — https://36kr.com/p/3846956646124036
6. 21st Century Business Herald — https://m.21jingji.com/article/20260918/herald/667d48b550b92631186b13511fc9c743.html
7. BioWorld — https://www.bioworld.com/keywords/59160-anew-therapeutics-pte-ltd